0001493152-23-041118.txt : 20231114 0001493152-23-041118.hdr.sgml : 20231114 20231114161548 ACCESSION NUMBER: 0001493152-23-041118 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231114 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Syra Health Corp CENTRAL INDEX KEY: 0001922335 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-EMPLOYMENT AGENCIES [7361] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41822 FILM NUMBER: 231406482 BUSINESS ADDRESS: STREET 1: 1119 KEYSTONE WAY N. STREET 2: #201 CITY: CARMEL STATE: IN ZIP: 46032 BUSINESS PHONE: (317) 922-0922 MAIL ADDRESS: STREET 1: 1119 KEYSTONE WAY N. STREET 2: #201 CITY: CARMEL STATE: IN ZIP: 46032 8-K 1 form8-k.htm
false 0001922335 0001922335 2023-11-14 2023-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2023

 

SYRA HEALTH CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41822   85-4027995

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I. R. S. Employer

Identification No.)

 

1119 Keystone Way N. #201

Carmel, IN 46032

(Address of principal executive offices, including zip code)

 

(463) 345-8950

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, $0.001 par value   SYRA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   
 

 

Item 2.02. Results of Operations and Financial Conditions.

 

On November 14, 2023, Syra Health Corp. issued a press release announcing its financial results for the third quarter of 2023 for the period ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

The information in this report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit.

 

Item 9.01 Financial Statements and Exhibit

 

(d) Exhibits.

 

The following exhibits are filed with this Current Report on Form 8-K:

 

Exhibit

Number

   Description
99.1   Press Release dated November 14, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SYRA HEALTH CORP.
     
Date: November 14, 2023 By: /s/ Deepika Vuppalanchi
    Deepika Vuppalanchi
    Chief Executive Officer

 

   

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Syra Health Announces Third Quarter 2023 Financial Results

 

Conference call will be held today, Tuesday, November 14 at 9:00am ET

 

Carmel, IN, November 14, 2023 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) a healthcare company addressing some of healthcare’s most significant challenges by providing innovative services and technology solutions, today announced its financial results for the third quarter of 2023 for the period ended September 30, 2023.

 

Q3 2023 Financial Highlights

 

  ● Revenue of $1.58 million, compared to $1.51 million in Q3 2022, an increase of 4%.
  ● Digital Health, driven by sales of the Company’s SyraBot product, had revenue of $131,356, marking its first period of revenues.
  ● Population Health and Health Education, driven by epidemiology and reporting services, saw revenues of $328,750, a 400% increase, compared to $66,000 in Q3 2022.
  ● Healthcare Workforce had revenue of $1.1 million in Q3 2023, in line with previous quarters.
  ● Gross profit margin of 35.1%, compared to 27.3% in Q3 2022.
  ● Net loss of $(354,376), compared to $(354,435) in Q3 2022.
  ● Adjusted EBITDA (see table A) was $(329,580), versus $(341,760) in Q3 2022.

 

Recent Operational Highlights

 

  ● Secured a five-year $4.75 million contract with the District of Columbia’s Department of Behavioral Health (DBH), to support DBH’s mental health initiatives, including its Supported Employment Program and Comprehensive Psychiatric Emergency Program.
  ● Received a two-year contract extension, worth up to $636,000, with the Indiana Division of Mental Health and Addiction and Family and Social Services Administration to chair and manage the State of Indiana’s Epidemiological Outcomes Workgroup.
  ● Formed a strategic agreement with Maricopa County Department of Public Health in Arizona to train over 100 public health staff in the county.
  ● Launched Syrenity, a mental health product that proactively identifies the negative factors impacting mental health and integrates telehealth for mental health prevention and treatment.
  ● Announced a strategic agreement with E&I Cooperative Services (E&I). Syra’s goal is to provide mental health services, including telehealth via Syrenity to E&I’s 6,000 plus college and university members nationwide.

 

 -1- 
 

 

  ● Launched CarePlus, an electronic medical record (EMR) system designed specifically for small to mid-sized healthcare organizations. CarePlus is an easy-to-use, secure, and scalable platform that allows for streamlining clinical workflows and integrating labs, radiology, and telehealth.
  ● In October 2023, closed on $6.7 million IPO financing and began trading on the NASDAQ.

 

Management Commentary

 

Dr. Deepika Vuppalanchi, CEO of Syra Health, said, “Our current and future pipeline of contracts is expanding, and we expect to announce contract wins as they are solidified. I look forward to building upon our recent successes to fulfill our promise of improving healthcare while driving value for our shareholders.”

 

Sandeep Allam, Executive Chairman and President of Syra Health, said, “We completed our successful initial public offering in October 2023. During the third quarter, we also saw our first revenues from our Digital Health business unit and expect revenue growth to continue as several products are launched. We also saw growth in our Population Health and Health Education Business Units. We are pleased with our third quarter performance and all that we have accomplished. We look forward to our continued growth and innovation next quarter and beyond.”

 

Q3 2023 Financial Results

 

Revenue for the quarter ended September 30, 2023, was $1.58 million, compared to the $1.51 million reported in the third quarter of 2022. Strong growth in the Digital Health, Population Health, and Health Education business units was offset by our Healthcare Workforce.

 

Gross profit for the quarter ended September 30, 2023, was $554,541, reflecting a gross profit margin of 35.1%, compared to $413,809 million, or a gross profit margin of 27.3%, in the third quarter of 2022. The increase in gross margins was due to a slight shift from healthcare staffing services to medical communication and digital health services that carry better margins.

 

Total operating expenses for the third quarter of 2023 increased 18% to $897,557, compared to $760,600 in the third quarter of 2022. Salaries and benefits expenses increased 31%, compared to the third quarter of 2022 due to increased operations and added office personnel to support the Company’s IPO process. Professional fees declined 62%, compared to the third quarter of 2022 due to decreased reliance on outsourced professional fees in connection with the prior period audit in preparation for the Company’s IPO. Selling, general and administrative expenses increased 56%, compared to the third quarter of 2022 due to increased operations. Depreciation expense was $14,180 in the third quarter of 2023, compared to $3,880 for the same period last year, reflecting expanded office space.

 

 -2- 
 

 

Net Loss for the quarter ended September 30, 2023, was $(354,376), compared to $(354,535) in the third quarter of 2022.

 

Adjusted EBITDA (see Table A) for the quarter ended September 30, 2023, was $(329,580), compared to $(341,760) in the third quarter of 2022.

 

Cash on hand September 30, 2023, was $18,010. Upon the closing of its IPO on October 3, 2023, the Company collected net proceeds of $4.7M.

 

Conference Call

 

Management will hold a conference call to discuss the quarter’s financial results at 9:00am ET on November 14, 2023.

 

Interested parties can listen via a live webcast, from the link available in the Investor Relations section of the Company’s website at https://ir.syrahealth.com/presentations or via https://app.webinar.net/QnrqX7vAKVL.

 

A replay will be available after the call, in the Investor Relations section of the Company’s website at https://ir.syrahealth.com/presentations .

 

Non-GAAP Financial Measures

 

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America (“GAAP”), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use these non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity, and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. We define Adjusted EBITDA as net earnings (loss) before (i) interest income, (ii) interest expense, (iii) change in allowance for doubtful accounts, (iv) depreciation, and (v) non-cash expenses relating to share-based payments recognized under ASC Topic 718. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see Table A accompanying this release.

 

 -3- 
 

 

SYRA HEALTH CORP.

RECONCILIATION OF ADJUSTED EBITDA TO NET LOSS

(Unaudited)

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
                 
Net loss  $(354,376)  $(354,535)  $(1,943,068)  $(1,505,533)
Add back:                    
Interest income   (2,820)   (35)   (2,826)   (54)
Interest expense   14,180    7,779    44,449    16,641 
Change in allowance for doubtful accounts   -    -    986    - 
Depreciation   12,357    3,880    36,413    4,791 
Stock based compensation   1,079    1,151    3,669    511,151 
Adjusted EBITDA  $(329,580)  $(341,760)  $(1,860,377)  $(973,004)

 

ABOUT SYRA HEALTH

 

Syra Health is a healthcare company addressing some of healthcare’s most significant challenges by providing innovative services and technology solutions. Syra Health specializes in behavioral and mental health, digital health, and population health. Syra Health’s solutions are centered on prevention, improved access, and affordable care. For more information, please visit www.syrahealth.com.

 

Forward-Looking Statements

 

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute ‘forward-looking statements.’ The words ‘anticipate,’ ‘believe,’ ‘continue,’ ‘could,’ ‘estimate,’ ‘expect,’ ‘intend,’ ‘may,’ ‘plan,’ ‘potential,’ ‘predict,’ ‘project,’ ‘should,’ ‘target,’ ‘will,’ ‘would’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Investors should read the risk factors set forth in our Form 10-Q for the quarter ended September 30, 2023, and in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syra Health specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

  

For more information, please contact:

 

Media:

 

Syra Health

Communications & Marketing Director

Christine Drury

317-385-9227

christined@syrahealth.com

 

Investors:

 

Ben Shamsian

Vice President

Lytham Partners, LLC

646-829-9701

shamsian@lythampartners.com

 

 -4- 
 

 

SYRA HEALTH CORP.

CONDENSED BALANCE SHEETS

 

   September 30,   December 31, 
   2023   2022 
   (Unaudited)     
ASSETS          
           
Current assets:          
Cash  $18,010   $3,344 
Accounts receivable, net   1,054,851    1,201,097 
Other current assets   163,323    222,302 
Total current assets   1,236,184    1,426,743 
           
Deferred offering costs   1,185,177    596,118 
Property and equipment, net   91,331    112,493 
Right-of-use asset   94,126    184,288 
           
Total assets  $2,606,818   $2,319,642 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable  $932,779   $432,388 
Accounts payable, related parties   21,421    3,200 
Accrued expenses   274,596    239,117 
Deferred revenue   141,644    - 
Current portion of operating lease liability, related party   94,126    121,089 
Revolving line of credit   300,154    750,551 
Advances from related party   616,399    - 
Total current liabilities   2,381,119    1,546,345 
           
Operating lease liability, related party   -    63,199 
Convertible notes payable   1,455,000    - 
           
Total liabilities   3,836,119    1,609,544 
           
Commitments and contingencies          
           
Stockholders’ equity (deficit):          
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding   -    - 
Class A common stock, $0.001 par value, 100,000,000 shares authorized, 3,527,092 and 3,568,758          
shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively   3,527    3,569 
Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 833,334 shares issued and outstanding   833    833 
Additional paid-in capital   2,836,019    2,832,308 
Accumulated deficit   (4,069,680)   (2,126,612)
Total stockholders’ equity (deficit)   (1,229,301)   710,098 
           
Total liabilities and stockholders’ equity (deficit)  $2,606,818   $2,319,642 

 

 -5- 
 

 

SYRA HEALTH CORP.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
                 
Net revenues:                    
Healthcare staffing services  $1,121,238   $1,447,979   $3,103,940   $3,366,667 
Medical communication services   328,750    66,000    513,647    285,311 
Digital health services   131,356    -    131,356    - 
Net revenues   1,581,344    1,513,979    3,748,943    3,651,978 
Cost of services   1,026,803    1,100,170    2,919,087    2,881,142 
Gross profit   554,541    413,809    829,856    770,836 
                     
Operating expenses:                    
Salaries and benefits   592,241    451,771    1,612,605    1,021,627 
Professional services   58,875    154,457    424,379    863,297 
Selling, general and administrative expenses   234,084    150,492    657,904    370,067 
Depreciation   12,357    3,880    36,413    4,791 
Total operating expenses   897,557    760,600    2,731,301    2,259,782 
                     
Operating loss   (343,016)   (346,791)   (1,901,445)   (1,488,946)
                     
Other income (expense):                    
Interest income   2,820    35    2,826    54 
Interest expense   (14,180)   (7,779)   (44,449)   (16,641)
Total other income (expense)   (11,360)   (7,744)   (41,623)   (16,587)
                     
Net loss  $(354,376)  $(354,535)  $(1,943,068)  $(1,505,533)
                     
Weighted average common shares outstanding - basic and diluted   4,360,426    4,107,164    4,380,267    2,337,915 
Net loss per common share - basic and diluted  $(0.08)  $(0.09)  $(0.44)  $(0.64)

 

 -6- 

 

 EX-101.SCH 3 syra-20231114.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 syra-20231114_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 syra-20231114_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 14, 2023
Entity File Number 001-41822
Entity Registrant Name SYRA HEALTH CORP.
Entity Central Index Key 0001922335
Entity Tax Identification Number 85-4027995
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1119 Keystone Way N. #201
Entity Address, City or Town Carmel
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46032
City Area Code (463)
Local Phone Number 345-8950
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.001 par value
Trading Symbol SYRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001922335 2023-11-14 2023-11-14 iso4217:USD shares iso4217:USD shares false 0001922335 8-K 2023-11-14 SYRA HEALTH CORP. DE 001-41822 85-4027995 1119 Keystone Way N. #201 Carmel IN 46032 (463) 345-8950 false false false false Class A Common Stock, $0.001 par value SYRA NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://syrahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm syra-20231114.xsd syra-20231114_lab.xml syra-20231114_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "SYRA", "nsuri": "http://syrahealth.com/20231114", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "syra-20231114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "syra-20231114_lab.xml" ] }, "presentationLink": { "local": [ "syra-20231114_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://syrahealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-23-041118-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-041118-xbrl.zip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end